Answers are grounded in this paper and cite their sources.
A retrospective study of 2764 patients was conducted at an HIV clinic in Nigeria to evaluate retention in care in patients treated for TB. At 6 and 12 months after commencement of TB treatment, 1842(66.6%) and 1624(58.8%) participants remained in care. Of the 922 and 1140 not in care at 6 and 12 months, 814(88.3%) and 1006(88.2%) respectively were lost to follow-up (LTFU). VL < 1000copies/ml was associated with higher odds of retention in care at 6 and 12 months (OR = 2.351 and 2.393) than VL > 1000 copies/ml. HAART use was associated with high likelihood of being in care at 12 months (OR = 3.980). CD4 counts of 200–350 and >350 cells/mm 3 were associated with increased odds of remaining in care at 12 months compared with CD4 < 200 cells/mm 3 (p = 0.005 and p = 0.001). Targeted interventions such as early HAART and close follow-up for high risk groups are likely to improve retention in care.
No takes yet. Share an insight, caveat, or question.
Adekanmbi et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: